European Journal of Clinical Pharmacology

, Volume 74, Issue 4, pp 521–524 | Cite as

Domperidone prolongs oral to duodenal transit time in video capsule endoscopy

  • Michael McfarlaneEmail author
  • B. Liu
  • C. Nwokolo
Pharmacoepidemiology and Prescription



Domperidone is thought to accelerate gastric emptying via D2 receptor antagonism at the gastro-oesophageal and gastro-duodenal junctions. Listed in the BNF as a prokinetic anti-emetic, it has been used in video capsule endoscopy (VCE) to accelerate capsule delivery to the small intestine. We audited VCEs performed at UHCW from 2011, when as standard practice, domperidone was given pre-VCE, to 2012, after its discontinuation due to doubts about its effectiveness.


Thirty-one patients received oral domperidone 20 mg pre-VCE. Thirty-three patients underwent VCE without domperidone pre-treatment. After 2 h, if the capsule remained intra-gastric, gastroscopy-assisted duodenal delivery was performed. Data was analysed using Mann-Whitney testing.


Median oro-duodenal transit was 13 and 30 min in the untreated and domperidone groups, respectively (p = 0.01). Median oro-caecal transit was 242 and 267 min in the untreated and domperidone groups, respectively (p = 0.02). No difference in duodenal-caecal transit was seen (p = 0.60). Six percent of untreated and 13% of domperidone VCEs required gastroscopy-assisted duodenal capsule delivery (p = 0.65).


Unexpectedly domperidone delayed VCE gastric transit. Most studies on domperidone prokinetic effects have been in diabetic gastroparesis, demonstrating that domperidone can achieve good symptomatic relief, but with mixed results for gastric emptying. Our study suggests that any antiemetic effects of domperidone are not mediated through accelerated gastric transit.


Capsule endoscopy Domperidone Prokinetic Gastric transit 


Author contributions

MM: Analysed the data and wrote the manuscript

BL: Collected the data

CN: Wrote the manuscript and project oversight

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.


  1. 1.
    Sneader W (2006) Drug discovery—a history. John Wiley & Sons, HobokenGoogle Scholar
  2. 2.
    Ahmad N, Keith-Ferris J, Gooden E, Abell T (2006) Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 6(6):571–576. CrossRefPubMedGoogle Scholar
  3. 3.
    Niemegeers CJ, Schellekens KH, Janssen PA (1980) The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther 244(1):130–140PubMedGoogle Scholar
  4. 4.
    Shuto K, Shiozaki Z, Kojima T, Tanaka M (1980) Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-DOPA. Aust J Pharm 3(12):709–714Google Scholar
  5. 5.
    Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24(5):360–400. CrossRefPubMedGoogle Scholar
  6. 6.
    Schuurkes JA, Van Nueten JM (1984) Control of gastroduodenal coordination: dopaminergic and cholinergic pathways. Scand J Gastroenterol Suppl 92:8–12PubMedGoogle Scholar
  7. 7.
    Joint Formulary Committee (2016) British National Formulary. BMJ Group and Pharmaceutical Press, LondonGoogle Scholar
  8. 8.
    Lee A (2013) Gastroparesis: what is the current state-of-the-art for evaluation and medical management? What are the results? J Gastrointest Surg 17(9):1553–1556. CrossRefPubMedGoogle Scholar
  9. 9.
    McAlindon ME, Ching HL, Yung D, Sidhu R, Koulaouzidis A (2016) Capsule endoscopy of the small bowel. Ann Transl Med 4(19):369. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sugumar A, Singh A, Pasricha PJ (2008) A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 6(7):726–733. CrossRefPubMedGoogle Scholar
  11. 11.
    Bateman DN, Gooptu D, Whittingham TA (1982) The effects of domperidone on gastric emptying of liquid in man. Br J Clin Pharmacol 13(5):675–678. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Broekaert A (1979) Effect of domperidone on gastric emptying and secretion. Postgrad Med J 55(Suppl 1):11–14PubMedGoogle Scholar
  13. 13.
    Baeyens R, van de Velde E, De Schepper A, Wollaert F, Reyntjens A (1979) Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgrad Med J 55(Suppl 1):19–23PubMedGoogle Scholar
  14. 14.
    Sanger GJ, Broad J, Andrews PL (2013) The relationship between gastric motility and nausea: gastric prokinetic agents as treatments. Eur J Pharmacol 715(1–3):10–14. CrossRefPubMedGoogle Scholar
  15. 15.
    Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F (2004) Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19(4):379–390. CrossRefPubMedGoogle Scholar
  16. 16.
    Sweetser S, Ravi K (2013) Gastrointestinal motility. In: DeCross AJ (ed) DDSEP7 Digestive Diseases Self-Education Program. AGA, Bethesda, pp 53–85Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of GastroenterologyUHCWCoventryUK

Personalised recommendations